CD93 and acute myeloid leukemia: This non-gated CAR-T demonstrated “on-target, on-tumor” cytotoxicity to CD93 + AML cells, while “on-target, off-tumor” effect to CD93 + immortalized human umbilical vein endothelial cells which was engineered to stably express truncated CD19, thus killing the AML cells but avoiding the toxicity to endothelial cell.